SiSaf Ltd
Charles Weatherstone has extensive work experience in the marketing and leadership roles. Charles began their career at Novartis as an International Marketing Manager in 1993. Charles then worked at Q-Med AB as the Head of International Marketing from 2002 to 2006. After that, Charles joined Allergan as the Facial Marketing Director EMEA from 2006 to 2008. Charles then moved to Ethicon, Inc. as a Global Strategic Marketing leader, where they developed and branded PDS Plates for nasal reconstruction and expanded the Mentor aesthetics portfolio. From 2012 to 2013, they worked as the Director of International Marketing at MyoScience, where they led corporate and product branding for the iovera° system. Charles later joined EternoGen as the Chief Commercial Officer, responsible for branding, fundraising, and strategic alliances. In 2014, Charles became the Marketing Director at B-Lite (G&G Biotechnology), where they developed and executed the brand and launch strategy for lightweight breast implants. Charles also managed an early exit process, leading to a merger with POLYTECH Health & Aesthetics GmbH. From 2017 to 2019, they served as the Interim CEO at Good Science Beauty, developing and launching a range of advanced skincare products. Currently, Charles is the Chief Marketing Officer at SISAF LTD, where they are responsible for corporate identity, awareness, strategic planning, fundraising, and partner negotiations.
Charles Weatherstone attended the University of Southampton from 1989 to 1991, where they pursued a Bachelor of Science degree in Marine Biology.
This person is not in any offices
SiSaf Ltd
SiSaf is an RNA delivery and therapeutics company. Its proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon.The company’s Bio-Courier portfolio includes silicon stabilized hybrid lipid nanoparticles (sshLNP) that improvethe stability, safety, and transfection efficiency of RNA. SiSaf uses sshLNP to develop a pipeline of RNA therapeutics for rare genetic disorders and is maximizing the potential of its technology through research partnerships.Led by founder and leading biomaterials specialist Dr Suzanne Saffie-Siebert, SiSaf is a venture capital backed private company. Headquartered in Guildford, UK, it has fully integrated research labs and bio-analytical facilities, a scalable technology to fast-track development, and a growing patent estate with extensive freedom to operate.